Congress mandates free HIV prevention drugs across all insurance plans

What it does

This bill requires all major health insurance plans—private insurance, Medicare, Medicaid, CHIP, and federal employee plans—to cover HIV prevention drugs (PrEP and PEP), related lab tests, counseling, and monitoring at no cost to patients. It eliminates copays, deductibles, and prior-authorization delays for these preventive services across all insurance types.

Why we flagged it

The bill's core function is to mandate no-cost coverage of HIV prevention services across all major insurance programs. It is straightforward public health policy with no hidden mechanisms or narrow carve-outs.

What the text implies

• Eliminates prior-authorization (preauth) delays for HIV prevention drugs, which may accelerate access to PrEP/PEP in urgent situations but could reduce insurers' ability to manage formulary costs.
• Applies uniformly across all insurance types (private, Medicare, Medicaid, CHIP, federal employees), creating a national standard that may pressure state Medicaid programs to absorb costs without additional federal funding.
• No explicit funding mechanism identified in the text; cost impact on federal and state budgets depends on uptake rates and drug pricing, which are not addressed.
• Counseling and monitoring requirements are tied to 'current US Public Health Service clinical practice guidelines,' which may shift over time and create ongoing compliance obligations.
• Medicaid and CHIP provisions allow states up to 1 year to implement if state legislation is required, creating a patchwork implementation timeline.

Who it affects

Ordinary people gain free access to proven HIV prevention medications and services without cost barriers or insurance delays. This removes financial obstacles to preventive care for a vulnerable population and reduces long-term public health costs by preventing infections.

Who stands to gain

• pharmaceutical manufacturers (PrEP/PEP drug makers)
• diagnostic testing providers
• clinical counseling and monitoring services

Named in the bill

FDA (Food and Drug Administration), CMS (Centers for Medicare & Medicaid Services), HHS (Department of Health and Human Services), Medicare Part B, Medicare Part D, Medicaid, CHIP (Children's Health Insurance Program), Federal Employees Health Benefits Program, Public Health Service

Where it stands

35 cosponsors: 35 Democrats.

• Sep 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 4, 2025 — Referred to House Committee on Oversight and Government Reform and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $690,000 in lobbying spend. A filing names 69 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Maxine Waters, the sponsor, reported $453,500 in PAC receipts in the 2026 cycle.

• National Treasury Employees Union — $690,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.